Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): November 16, 2010
_____________________
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
_____________________
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM
7.01
|
REGULATION
FD DISCLOSURE
|
On
November 15, 2010, Oramed Pharmaceuticals Inc. issued a press release announcing
that it presented the results of its recently completed Phase IIb trial. The
multicenter, placebo-controlled, randomized, double-blind study conducted in 29
patients with Type II diabetes assessed the safety of ORMD-0801 in patients with
Type II diabetes. Results were presented by the company’s Chief Scientific
Officer, Dr. Miriam Kidron, at the Tenth Annual Meeting of the Diabetes
Technology Society, in Bethesda, Maryland.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.1
and is incorporated by reference herein.
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated November 15, 2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
ORAMED PHARMACEUTICALS
INC.
|
Dated:
November 16, 2010
|
|
|
|
|
|
By:
|
/s/
Nadav Kidron
|
|
|
|
Nadav
Kidron
|
|
|
|
President,
CEO and Director
|
Exhibit
Index
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated November 15, 2010.
|